Interim results from the low-dose cohort of the PROCLAIM trial show that AAV-based delivery of the progranulin gene in patients with frontotemporal dementia was safe and was associated with increased CSF progranulin.
- Jeffrey Sevigny
- Olga Uspenskaya
- Franz Hefti